441 related articles for article (PubMed ID: 34524579)
1. MicroRNAs as a clue to overcome breast cancer treatment resistance.
Garrido-Cano I; Pattanayak B; Adam-Artigues A; Lameirinhas A; Torres-Ruiz S; Tormo E; Cervera R; Eroles P
Cancer Metastasis Rev; 2022 Mar; 41(1):77-105. PubMed ID: 34524579
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
3. The Role of MicroRNAs in the Chemoresistance of Breast Cancer.
Wang J; Yang M; Li Y; Han B
Drug Dev Res; 2015 Nov; 76(7):368-74. PubMed ID: 26310899
[TBL] [Abstract][Full Text] [Related]
4. Regulation of epithelial-mesenchymal transition through microRNAs: clinical and biological significance of microRNAs in breast cancer.
Peng F; Xiong L; Tang H; Peng C; Chen J
Tumour Biol; 2016 Nov; 37(11):14463-14477. PubMed ID: 27644253
[TBL] [Abstract][Full Text] [Related]
5. The role of microRNAs on doxorubicin drug resistance in breast cancer.
Jamialahmadi K; Zahedipour F; Karimi G
J Pharm Pharmacol; 2021 Jul; 73(8):997-1006. PubMed ID: 33942851
[TBL] [Abstract][Full Text] [Related]
6. Role of miR-155 in drug resistance of breast cancer.
Yu DD; Lv MM; Chen WX; Zhong SL; Zhang XH; Chen L; Ma TF; Tang JH; Zhao JH
Tumour Biol; 2015 Mar; 36(3):1395-401. PubMed ID: 25744731
[TBL] [Abstract][Full Text] [Related]
7. EMT in breast cancer metastasis: an interplay of microRNAs, signaling pathways and circulating tumor cells.
Kumar A; Golani A; Kumar LD
Front Biosci (Landmark Ed); 2020 Mar; 25(5):979-1010. PubMed ID: 32114421
[TBL] [Abstract][Full Text] [Related]
8. A summary for molecular regulations of miRNAs in breast cancer.
Yahya SM; Elsayed GH
Clin Biochem; 2015 Apr; 48(6):388-96. PubMed ID: 25541018
[TBL] [Abstract][Full Text] [Related]
9. miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer.
Fu H; Fu L; Xie C; Zuo WS; Liu YS; Zheng MZ; Yu JM
Oncol Rep; 2017 Feb; 37(2):1093-1099. PubMed ID: 28075453
[TBL] [Abstract][Full Text] [Related]
10. miR-93 and PTEN: Key regulators of doxorubicin-resistance and EMT in breast cancer.
Chu S; Liu G; Xia P; Chen G; Shi F; Yi T; Zhou H
Oncol Rep; 2017 Oct; 38(4):2401-2407. PubMed ID: 28765915
[TBL] [Abstract][Full Text] [Related]
11. miR‑125a‑5p reverses epithelial‑mesenchymal transition and restores drug sensitivity by negatively regulating TAFAZZIN signaling in breast cancer.
Li D; Chen L; Zhang X; Wang Y; Huang C; Li J; He F; He W
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34549308
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.
Bockhorn J; Dalton R; Nwachukwu C; Huang S; Prat A; Yee K; Chang YF; Huo D; Wen Y; Swanson KE; Qiu T; Lu J; Park SY; Dolan ME; Perou CM; Olopade OI; Clarke MF; Greene GL; Liu H
Nat Commun; 2013; 4():1393. PubMed ID: 23340433
[TBL] [Abstract][Full Text] [Related]
13. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
[TBL] [Abstract][Full Text] [Related]
14. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.
García-Becerra R; Santos N; Díaz L; Camacho J
Int J Mol Sci; 2012 Dec; 14(1):108-45. PubMed ID: 23344024
[TBL] [Abstract][Full Text] [Related]
16. The role of p53-microRNA 200-Moesin axis in invasion and drug resistance of breast cancer cells.
Alam F; Mezhal F; El Hasasna H; Nair VA; Aravind SR; Saber Ayad M; El-Serafi A; Abdel-Rahman WM
Tumour Biol; 2017 Sep; 39(9):1010428317714634. PubMed ID: 28933253
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells.
Yan L; Yang S; Yue CX; Wei XY; Peng W; Dong ZY; Xu HN; Chen SL; Wang WR; Chen CJ; Yang QL
Environ Toxicol; 2020 Sep; 35(9):1015-1028. PubMed ID: 32420678
[TBL] [Abstract][Full Text] [Related]
18. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
BeLow M; Osipo C
Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
[TBL] [Abstract][Full Text] [Related]
19. Tumor-promoting properties of miR-8084 in breast cancer through enhancing proliferation, suppressing apoptosis and inducing epithelial-mesenchymal transition.
Gao Y; Ma H; Gao C; Lv Y; Chen X; Xu R; Sun M; Liu X; Lu X; Pei X; Li P
J Transl Med; 2018 Feb; 16(1):38. PubMed ID: 29471858
[TBL] [Abstract][Full Text] [Related]
20. A bioinformatics approach for identification of miR-100 targets implicated in breast cancer.
Shamsi R; Seifi-Alan M; Behmanesh A; Omrani MD; Mirfakhraie R; Ghafouri-Fard S
Cell Mol Biol (Noisy-le-grand); 2017 Oct; 63(10):99-105. PubMed ID: 29096749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
